Open AccessEstimating the risk of thrombotic events in people with congenital hemophilia A using US claims data
Author(s) -
Imi Faghmous,
Francis Nissen,
Peter Kuebler,
Carlos Flores,
Anisha M Patel,
Steven W. Pipe
Publication year - 2021
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2021-0120
Subject(s) - medicine , pulmonary embolism , deep vein , thrombosis , incidence (geometry) , stroke (engine) , myocardial infarction , population , cardiology , context (archaeology) , cohort , mechanical engineering , paleontology , physics , environmental health , optics , biology , engineering
Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.